COVID,O
‐,O
19,NUMBER
Clinical,O
Research,O
Jeffrey,PERSON
Chi,PERSON
.,O
David,PERSON
Chitty,PERSON
.,O
Meeyoung,PERSON
Lee,PERSON
.,O
Nausheen,PERSON
Hakim,PERSON
.,O
Shamsah,PERSON
Lakhani,PERSON
.,O
Lakshmi,PERSON
Rajdev,PERSON
.,O
Xinhua,PERSON
Zhu,PERSON
.,O
Muhammad,PERSON
Wasif,PERSON
Saif,PERSON
*,O
Introduction,O
:,O
While,O
the,O
global,O
COVID,O
‐,O
19,NUMBER
pan,O
‐,O
demic,O
has,O
challenged,O
the,O
entire,O
humanity,O
and,O
health,O
systems,O
.,O
it,O
also,O
triggered,O
researchers,O
to,O
urgently,O
perform,O
clinical,O
trials,O
to,O
assess,O
the,O
safety,O
and,O
efficacy,O
of,O
many,O
agents,O
and,O
modalities,O
to,O
combat,O
COVID,O
‐,O
19,NUMBER
.,O
As,O
of,O
April,DATE
22,DATE
.,O
over,O
650,NUMBER
clinical,O
studies,O
have,O
been,O
registered,O
both,O
in,O
USA,COUNTRY
and,O
internationally,O
.,O
Results,O
from,O
these,O
studies,O
are,O
also,O
coming,O
at,O
a,O
brisk,O
pace,O
in,O
this,O
unprece,O
‐,O
dented,O
emergency,O
.,O
Areas,O
covered,O
:,O
We,O
searched,O
the,O
NCI,ORGANIZATION
website,O
and,O
Medline,ORGANIZATION
and,O
summarize,O
various,O
national,O
and,O
international,O
clinical,O
trials,O
and,O
summarize,O
few,O
of,O
the,O
pivotal,O
ones,O
in,O
this,O
paper,O
.,O
in,O
‐,O
cluding,O
those,O
specific,O
to,O
oncology,O
population,O
.,O
Two,NUMBER
hundred,NUMBER
and,O
eighty,NUMBER
four,NUMBER
studies,O
are,O
actively,O
recruiting,O
adults,O
and,O
children,O
with,O
confirmed,O
COVID,O
‐,O
19,NUMBER
.,O
including,O
25,NUMBER
are,O
early,O
‐,O
phase,O
I,O
/,O
phase,O
I,O
.,O
72,NUMBER
phase,O
II,NUMBER
.,O
58,NUMBER
phase,O
III,NUMBER
.,O
12,NUMBER
phase,O
IV,O
.,O
and,O
31,NUMBER
other,O
trials,O
.,O
They,O
can,O
be,O
categorized,O
into,O
four,NUMBER
groups,O
:,O
drugs,CRIMINAL_CHARGE
that,O
combat,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
immunomodulatory,O
agents,O
to,O
counteract,O
cytokine,O
storm,CAUSE_OF_DEATH
.,O
con,O
‐,O
valescence,O
plasma,O
therapies,O
and,O
vaccines,O
trials,O
.,O
Expert,O
opinion,O
:,O
It,O
is,O
hoped,O
that,O
these,O
efforts,O
will,O
results,O
in,O
a,O
successful,O
treatment,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
especially,O
in,O
a,O
timely,O
fashion,O
before,O
the,O
second,ORDINAL
pandemic,O
expected,O
in,O
fall,DATE
.,O
It,O
is,O
essential,O
to,O
acknowledge,O
the,O
devotion,O
and,O
hard,O
work,O
of,O
the,O
clinical,O
research,O
team,O
and,O
clinical,O
research,O
COVID,O
‐,O
19,NUMBER
;,O
Immunosuppression,O
;,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
;,O
Im,O
‐,O
munomodulatory,O
;,O
Cytokine,O
storm,CAUSE_OF_DEATH
;,O
Convalescent,O
plasma,O
;,O
Vaccines,O
;,O
BCG,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
causes,O
the,O
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
which,O
was,O
first,ORDINAL
detected,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
in,O
December,DATE
2019,DATE
.,O
Since,O
then,O
it,O
has,O
spread,O
to,O
more,O
than,O
200,NUMBER
countries,O
.,O
As,O
of,O
April,DATE
20,DATE
.,DATE
2020,DATE
.,O
there,O
have,O
been,O
more,O
than,O
2.5,NUMBER
million,NUMBER
reported,O
cases,O
and,O
170.000,NUMBER
deaths,O
worldwide,O
[,O
1,NUMBER
],O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
a,O
positive,O
sense,O
.,O
single,O
‐,O
strand,O
enveloped,O
RNA,O
virus,O
that,O
shares,O
close,O
genetic,O
similarity,O
to,O
corona,O
viruses,O
from,O
previous,O
outbreaks,O
‐,O
the,O
severe,O
acute,O
res,O
‐,O
piratory,O
Chi,O
et,O
al,O
.,O
syndrome,O
corona,O
virus,O
(,O
SARS,O
‐,O
COV,O
),O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
‐,O
CoV,O
),O
.,O
The,O
common,O
man,O
‐,O
ifestations,O
from,O
COVID,O
‐,O
19,NUMBER
are,O
cough,O
(,O
86.1,PERCENT
%,PERCENT
),O
.,O
fever,CAUSE_OF_DEATH
or,O
chills,O
(,O
85.0,PERCENT
%,PERCENT
),O
.,O
and,O
shortness,O
of,O
breath,O
(,O
80.0,PERCENT
%,PERCENT
),O
which,O
are,O
very,O
similar,O
to,O
influenza,CAUSE_OF_DEATH
but,O
the,O
case,O
fatality,O
rate,O
of,O
COVID,O
‐,O
19,NUMBER
is,O
much,O
high,O
and,O
estimated,O
to,O
be,O
at,O
310,PERCENT
%,PERCENT
.,O
Diabetes,CAUSE_OF_DEATH
mellitus,CAUSE_OF_DEATH
.,O
cardiovascular,O
disease,CAUSE_OF_DEATH
.,O
hypertension,CAUSE_OF_DEATH
.,O
chronic,O
lung,O
disease,CAUSE_OF_DEATH
.,O
and,O
obesity,O
are,O
some,O
of,O
the,O
prevalent,O
conditions,O
that,O
may,O
increase,O
the,O
risk,O
of,O
hospi,O
‐,O
talizations,O
[,O
2,NUMBER
],O
.,O
The,O
severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
with,O
high,O
mortality,O
are,O
associated,O
with,O
reduced,O
innate,O
and,O
adaptive,O
immune,O
responses,O
in,O
conjunction,O
with,O
abundant,O
cytokine,O
and,O
overexpression,O
of,O
in,O
‐,O
terleukin,O
6,NUMBER
(,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
),O
[,O
3.4,NUMBER
],O
.,O
These,O
patients,O
present,DATE
with,O
lymphopenia,O
with,O
markedly,O
decreased,O
number,O
of,O
CD4,O
and,O
CD8,O
T,O
cells,O
.,O
natural,O
killer,O
cells,O
and,O
monocytes,O
[,O
4,NUMBER
],O
.,O
The,O
United,ORGANIZATION
States,ORGANIZATION
Food,ORGANIZATION
and,ORGANIZATION
Drug,ORGANIZATION
compassionate,O
use,O
in,O
treating,O
patients,O
with,O
COVID,O
19,NUMBER
.,O
Although,O
there,O
are,O
many,O
ongoing,O
clinical,O
trials,O
.,O
currently,DATE
there,O
is,O
no,O
strong,O
evidence,O
from,O
clinical,O
trials,O
.,O
treatment,O
strategies,O
.,O
and,O
clinical,O
experience,O
in,O
treating,O
COVID,O
‐,O
19,NUMBER
with,O
a,O
focus,O
on,O
oncology,O
patients,O
.,O
The,O
Current,DATE
Landscape,O
of,O
Clinical,O
Trials,O
for,O
COVID,O
‐,O
19,NUMBER
Currently,DATE
there,O
are,O
657,NUMBER
registered,O
clinical,O
trials,O
related,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
as,O
of,O
April,DATE
20th,DATE
.,DATE
2020,DATE
.,O
Of,O
these,O
trials,O
.,O
284,NUMBER
are,O
ac,O
‐,O
tively,O
recruiting,O
adults,O
and,O
children,O
with,O
confirmed,O
COVID,O
‐,O
19,NUMBER
for,O
in,O
‐,O
patient,O
and,O
outpatient,O
pharmacological,O
interventions,O
.,O
Of,O
the,O
284,NUMBER
trials,O
.,O
25,NUMBER
are,O
Early,O
‐,O
phase,O
I,O
/,O
Phase,O
I,O
.,O
72,NUMBER
Phase,O
II,NUMBER
.,O
58,NUMBER
Phase,O
III,NUMBER
.,O
12,NUMBER
Phase,O
IV,O
.,O
and,O
31,NUMBER
other,O
trials,O
.,O
They,O
can,O
be,O
categorized,O
into,O
1,NUMBER
),O
drugs,CRIMINAL_CHARGE
that,O
combat,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
2,NUMBER
),O
immunomodulatory,O
agents,O
to,O
Trials,O
with,O
Drugs,CRIMINAL_CHARGE
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Viral,O
Replication,O
Many,O
agents,O
in,O
this,O
category,O
are,O
already,O
approved,O
by,O
the,O
FDA,ORGANIZATION
for,O
treating,O
other,O
diseases,CAUSE_OF_DEATH
.,O
They,O
have,O
generally,O
have,O
proven,O
safety,O
profile,O
and,O
tolerability,O
from,O
previous,O
clinical,O
experience,O
.,O
In,O
vitro,O
studies,O
of,O
these,O
agents,O
showed,O
antiviral,O
activities,O
against,O
SARS,O
‐,O
VoV,O
‐,O
2,NUMBER
Chloroquine,O
and,O
its,O
derivative,O
.,O
Hydroxychloroquine,LOCATION
.,O
have,O
been,O
widely,O
used,O
to,O
treat,O
malarial,O
and,O
autoimmune,O
disease,CAUSE_OF_DEATH
.,O
Chloroquine,O
blocks,O
virus,O
infection,CAUSE_OF_DEATH
by,O
raising,O
endosomal,O
pH,COUNTRY
re,O
‐,O
quired,O
for,O
virus,O
‐,O
cell,O
fusion,O
and,O
interferes,O
with,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
re,O
‐,O
ceptor,O
glycosylation,O
[,O
5,NUMBER
],O
.,O
It,O
has,O
also,O
been,O
shown,O
to,O
have,O
similar,O
inhibitory,O
effects,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
6,NUMBER
],O
.,O
A,O
recent,O
Chinese,NATIONALITY
study,O
showed,O
that,O
Hydroxychloroquine,PERSON
was,O
more,O
potent,O
and,O
tolerable,O
than,O
chloroquine,O
in,O
vitro,O
[,O
7,NUMBER
],O
.,O
In,O
a,O
recent,O
open,O
‐,O
label,O
.,O
non,O
‐,O
randomized,O
trial,O
.,O
Gautret,PERSON
et,O
al.,O
showed,O
significant,O
reduction,O
in,O
viral,O
load,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
treated,O
with,O
hydroxychloroquine,O
[,O
8,NUMBER
],O
.,O
Another,O
observational,O
study,O
with,O
1061,NUMBER
patients,O
who,O
received,O
hydroxy,O
‐,O
chloroquine,O
and,O
azithromycin,O
showed,O
good,O
viral,O
clearance,O
and,O
safety,O
profile,O
[,O
9,NUMBER
],O
.,O
Currently,DATE
.,O
there,O
are,O
101,NUMBER
clinical,O
trials,O
worldwide,O
using,O
hydroxychloroquine,O
either,O
by,O
itself,O
or,O
in,O
combi,O
‐,O
nation,O
with,O
other,O
agents,O
for,O
treating,O
COVID,O
‐,O
19,NUMBER
[,O
10,NUMBER
],O
.,O
Chi,O
et,O
al,O
.,O
Remdesivir,O
is,O
an,O
adenosine,O
analogue,O
.,O
It,O
causes,O
premature,O
termina,O
‐,O
tion,O
of,O
viral,O
RNA,O
replication,O
when,O
incorporated,O
into,O
growing,O
RNA,O
.,O
It,O
was,O
initially,O
developed,O
as,O
a,O
trial,O
drug,O
for,O
treatment,O
of,O
Ebola,O
during,O
the,O
height,O
of,O
Ebola,MISC
outbreak,O
.,O
However,O
.,O
the,O
phase,O
3,NUMBER
random,O
‐,O
ized,O
trial,O
yielded,O
negative,O
result,O
[,O
11,NUMBER
],O
.,O
Nevertheless,O
.,O
it,O
showed,O
significant,O
in,O
vitro,O
antiviral,O
activity,O
against,O
a,O
wide,O
array,O
of,O
RNA,O
viruses,O
in,O
the,O
Flaviviridae,O
and,O
Corona,O
viridae,O
family,O
includ,O
‐,O
ing,O
SARS,O
‐,O
CoV,O
.,O
MERS,O
‐,O
CoV,O
and,O
most,O
recently,DATE
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
6,NUMBER
],O
.,O
There,O
have,O
been,O
reports,O
of,O
anecdotal,O
successful,O
use,O
of,O
remdesivir,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
[,O
12.13,NUMBER
],O
.,O
Currently,DATE
there,O
are,O
many,O
ongoing,O
clinical,O
trials,O
(,O
e.g.,O
NCT04292899,O
.,O
NCT04292730,O
),O
to,O
evaluate,O
the,O
efficacy,O
of,O
remdesivir,O
in,O
patients,O
with,O
mild,O
to,O
moderate,O
or,O
se,O
‐,O
vere,O
COVID,O
‐,O
19,NUMBER
.,O
For,O
severe,O
patients,O
.,O
the,O
data,O
for,O
the,O
first,ORDINAL
400,NUMBER
patients,O
in,O
the,O
study,O
was,O
finished,O
.,O
will,O
be,O
released,O
any,O
day,DURATION
(,O
NCT04292899,O
),O
.,O
Lopinavir,O
‐,O
ritonavir,O
is,O
an,O
FDA,ORGANIZATION
approved,O
combina,O
‐,O
tion,O
antiviral,O
medication,O
used,O
to,O
treat,O
and,O
prevent,O
HIV,CAUSE_OF_DEATH
.,O
It,O
was,O
used,O
in,O
the,O
2003,DATE
SARS,O
outbreak,O
and,O
associated,O
reduced,O
mortality,O
and,O
intubation,O
rates,O
[,O
14,NUMBER
],O
.,O
In,O
terms,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
early,O
case,O
re,O
‐,O
ports,O
and,O
observational,O
studies,O
showed,O
mix,O
results,O
[,O
14,NUMBER
],O
.,O
However,O
.,O
a,O
recent,O
open,O
label,O
randomized,O
trial,O
in,O
China,COUNTRY
with,O
199,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
failed,O
to,O
show,O
significant,O
difference,O
in,O
viral,O
clearance,O
or,O
28,NUMBER
‐,O
day,DURATION
mortality,O
rates,O
[,O
15,NUMBER
],O
.,O
Although,O
there,O
are,O
ad,O
‐,O
ditional,O
RCTs,O
ongoing,O
.,O
the,O
current,DATE
data,O
suggest,O
a,O
limited,O
role,O
of,O
the,O
drug,O
in,O
COVID,O
‐,O
19,NUMBER
treatment,O
.,O
Arbidol,O
(,O
Umifenovir,LOCATION
),O
targets,O
S,O
protein,O
/,O
ACE2,O
interaction,O
.,O
then,O
inhibits,O
membrane,O
fusion,O
of,O
the,O
viral,O
envelope,O
.,O
It,O
is,O
approved,O
for,O
treatment,O
of,O
influenza,CAUSE_OF_DEATH
in,O
Chi,O
‐,O
na,O
and,O
Russia,COUNTRY
.,O
There,O
are,O
total,O
of,O
4,NUMBER
trials,O
available,O
with,O
2,NUMBER
re,O
‐,O
cruiting,O
for,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Camostat,O
mesylate,O
inhibits,O
transmembrane,O
serine,O
protease,O
and,O
prevents,O
viral,O
cell,O
entry,O
.,O
It,O
is,O
primarily,O
used,O
to,O
treat,O
postoperative,O
reflux,O
esophagitis,O
and,O
acute,O
pancreatitis,CAUSE_OF_DEATH
in,O
Japan,COUNTRY
.,O
There,O
are,O
4,NUMBER
trials,O
available,O
with,O
2,NUMBER
recruiting,O
for,O
CoViD,O
‐,O
19,NUMBER
patients,O
.,O
Immunomodulatory,O
Agents,O
against,O
Cytokine,O
Storm,CAUSE_OF_DEATH
One,NUMBER
of,O
the,O
hallmarks,O
of,O
COVID,O
‐,O
19,NUMBER
disease,CAUSE_OF_DEATH
course,O
is,O
that,O
is,O
that,O
the,O
patients,O
can,O
rapidly,O
develop,O
acute,O
respiratory,O
distress,O
syndrome,O
and,O
multiple,O
‐,O
organ,O
failure,O
leading,O
to,O
death,O
.,O
Overwhelming,O
cytokine,O
storm,CAUSE_OF_DEATH
is,O
one,NUMBER
to,O
the,O
major,O
con,O
‐,O
tributors,O
to,O
the,O
rapid,O
clinical,O
decline,O
.,O
Potent,O
cytokines,O
such,O
as,O
interleukin,O
(,O
IL,STATE_OR_PROVINCE
),O
1,NUMBER
.,O
IL2,O
.,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
.,O
TNFa,O
.,O
IFN,ORGANIZATION
‐,O
.,O
were,O
noted,O
to,O
be,O
markedly,O
elevated,O
in,O
these,O
patients,O
.,O
Various,O
immunomodulatory,O
agents,O
are,O
being,O
studied,O
in,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
to,O
abate,O
the,O
cytokine,O
storm,CAUSE_OF_DEATH
.,O
Tocilizumab,PERSON
.,O
an,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
receptor,O
antago,O
‐,O
nist,O
.,O
approved,O
for,O
treatment,O
of,O
cytokine,O
storm,CAUSE_OF_DEATH
due,O
to,O
CAR,O
‐,O
T,O
cell,O
therapy,O
.,O
giant,O
cell,O
arteritis,O
and,O
rheumatoid,O
arthritis,O
(,O
RA,O
),O
.,O
has,O
been,O
used,O
to,O
treat,O
severe,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
cytokine,O
storm,CAUSE_OF_DEATH
.,O
A,O
report,O
of,O
21,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
treated,O
with,O
tocilizumab,O
showed,O
improvements,O
in,O
terms,O
of,O
respiratory,O
function,O
.,O
rapid,O
defferves,O
‐,O
cence,O
and,O
early,O
hospital,O
discharge,O
[,O
16,NUMBER
],O
.,O
Ongoing,O
clinical,O
trials,O
include,O
NCT04310228,O
.,O
ChiCTR200002976,O
.,O
Sarilumab,PERSON
.,O
another,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
re,O
‐,O
ceptor,O
antagonist,O
approved,O
for,O
RA,O
.,O
is,O
also,O
being,O
studied,O
in,O
clin,O
‐,O
ical,O
trials,O
(,O
e.g.,O
NCT04288713,O
),O
in,O
hospitalized,O
patients,O
Chi,PERSON
et,O
al,O
.,O
Anakinra,LOCATION
is,O
an,O
IL,STATE_OR_PROVINCE
‐,O
1,NUMBER
receptor,O
antagonist,O
(,O
IL,STATE_OR_PROVINCE
‐,O
1ra,O
),O
approved,O
for,O
RA,O
and,O
neonatal,O
onset,O
multisystem,O
inflammatory,O
disease,CAUSE_OF_DEATH
(,O
NO,O
‐,O
MID,O
),O
.,O
It,O
can,O
block,O
IL,STATE_OR_PROVINCE
‐,O
1,NUMBER
and,O
the,O
downstream,O
inflammatory,O
effects,O
.,O
decreasing,O
/,O
stopping,O
the,O
cytokine,O
storm,CAUSE_OF_DEATH
.,O
It,O
is,O
being,O
studied,O
in,O
clinical,O
trials,O
NCT04339712,O
.,O
NCT04341584,O
.,O
It,O
is,O
also,O
being,O
stud,O
‐,O
ied,O
in,O
combination,O
with,O
emapalumab,O
(,O
NCT04324021,O
),O
.,O
a,O
monoclonal,O
antibody,O
against,O
IFN,O
‐,O
approved,O
for,O
refractory,O
hemophagocytic,O
lym,O
‐,O
phohistiocytosis,O
(,O
HLH,O
),O
.,O
Roxolitinib,O
is,O
an,O
inhibitor,O
of,O
Janus,O
Ki,O
‐,O
nase,O
(,O
JAK,O
),O
1,NUMBER
and,O
JAK2,O
approved,O
for,O
the,O
treatment,O
of,O
myelofibro,O
‐,O
sis,O
.,O
polycythemia,O
vera,O
.,O
and,O
graft,O
‐,O
versus,O
‐,O
host,TITLE
disease,CAUSE_OF_DEATH
.,O
The,O
JAK,O
pathway,O
is,O
a,O
potential,O
target,O
as,O
IFN,O
‐,O
exerts,O
its,O
inflammatory,O
ef,O
‐,O
fects,O
via,O
the,O
JAK,O
/,O
STAT,O
pathway,O
.,O
It,O
can,O
block,O
the,O
downstream,O
ef,O
‐,O
fects,O
of,O
IFN,O
‐,O
and,O
other,O
cytokines,O
reducing,O
inflammation,O
.,O
Cur,O
‐,O
rently,O
there,O
are,O
ongoing,O
clinical,O
trials,O
(,O
NCT04331665,O
.,O
NCT04338958,O
),O
to,O
study,O
its,O
efficacy,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Se,O
‐,O
linexor,O
.,O
a,O
nuclear,O
export,O
protein,O
(,O
XPO1,O
),O
inhibitor,O
approved,O
for,O
treatment,O
of,O
relapsed,O
/,O
refractory,O
multiple,CAUSE_OF_DEATH
myeloma,CAUSE_OF_DEATH
is,O
another,O
po,O
‐,O
tential,O
agent,O
to,O
treat,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Zhou,PERSON
et,O
al.,O
showed,O
that,O
both,O
SAR,O
‐,O
CoV,O
‐,O
2,NUMBER
propagation,O
in,O
host,TITLE
cells,O
and,O
inflammatory,O
tran,O
‐,O
scription,O
factors,O
require,O
functional,O
nuclear,O
transport,O
protein,O
XPO1,O
[,O
17,NUMBER
],O
.,O
Selinexor,O
can,O
potentially,O
stop,O
viral,O
replication,O
and,O
cytokine,O
storm,CAUSE_OF_DEATH
at,O
the,O
same,O
time,O
.,O
Its,O
efficacy,O
in,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients,O
is,O
being,O
evaluated,O
in,O
a,O
clinical,O
trial,O
(,O
NCT04349098,O
),O
.,O
Acalabrutinib,O
is,O
a,O
Brutons,MISC
tyrosine,O
kinase,O
(,O
BTK,O
),O
inhibitor,O
ap,O
‐,O
proved,O
for,O
treatment,O
of,O
chronic,O
lymphocytic,O
leukemia,CAUSE_OF_DEATH
and,O
mantle,O
cell,O
lymphoma,CAUSE_OF_DEATH
.,O
BTK,O
is,O
a,O
key,O
regulator,O
of,O
production,O
of,O
multiple,O
cytokines,O
and,O
chemokines,O
including,O
TNF,O
‐,O
.,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
.,O
IL,STATE_OR_PROVINCE
‐,O
10,NUMBER
.,O
and,O
MCP,ORGANIZATION
‐,O
1,NUMBER
identified,O
as,O
elevated,O
in,O
severe,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
A,O
new,O
study,O
in,O
Spain,COUNTRY
is,O
underway,O
(,O
NCT04346199,O
),O
to,O
study,O
acalaburtinib,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Convalescent,O
plasma,O
The,O
use,O
of,O
convalescent,O
plasma,O
and,O
passive,O
immunization,O
has,O
been,O
studied,O
in,O
the,O
treatment,O
of,O
respiratory,O
viral,O
illnesses,O
(,O
influenza,CAUSE_OF_DEATH
.,O
SARS,O
‐,O
CoV,O
.,O
MERS,O
‐,O
CoV,O
),O
and,O
preliminary,O
data,O
suggests,O
that,O
convalescent,O
plasma,O
may,O
be,O
of,O
benefit,O
in,O
some,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
[,O
18.19,NUMBER
],O
.,O
Specifically,O
.,O
in,O
a,O
Chinese,NATIONALITY
study,O
of,O
5,NUMBER
critically,O
‐,O
ill,O
COVID,O
‐,O
19,NUMBER
patients,O
on,O
mechani,O
‐,O
cal,O
ventilation,O
.,O
a,O
one,NUMBER
‐,O
time,O
administration,O
of,O
convalescent,O
plasma,O
resulted,O
in,O
clinical,O
improvement,O
of,O
all,O
patients,O
.,O
with,O
3,NUMBER
patients,O
being,O
weaned,O
off,O
mechanical,O
ventilation,O
within,O
As,O
of,O
April,DATE
19,DATE
.,O
2020,DATE
.,O
there,O
were,O
5,NUMBER
registered,O
convalescent,O
plasma,O
therapy,O
clini,O
‐,O
cal,O
trials,O
in,O
COVID,O
‐,O
19,NUMBER
convalescent,O
plasma,O
can,O
be,O
isolated,O
from,O
the,O
blood,O
of,O
patients,O
who,O
have,O
recovered,O
from,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
and,O
are,O
believed,O
to,O
have,O
developed,O
humoral,O
immunity,O
against,O
the,O
virus,O
.,O
The,O
collected,O
convalescent,O
plasma,O
can,O
then,O
be,O
trans,O
‐,O
fused,O
into,O
ABO,O
compatible,O
severe,O
or,O
critically,O
ill,O
patients,O
with,O
active,O
COVID,O
‐,O
19,NUMBER
.,O
Chi,O
et,O
al,O
.,O
Vaccine,O
Trials,O
Effective,O
vaccina,O
‐,O
tion,O
to,O
a,O
large,O
portion,O
of,O
the,O
worlds,O
population,O
is,O
needed,O
to,O
ef,O
‐,O
fectively,O
end,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
Since,O
the,O
World,O
Health,O
Orga,O
‐,O
nization,O
declared,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
as,O
a,O
pandemic,O
in,O
early,O
March,DATE
.,O
tremendous,O
effort,O
and,O
funding,O
have,O
been,O
allocated,O
to,O
de,O
‐,O
veloping,O
vaccines,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
DNA,O
and,O
RNA,O
‐,O
based,O
vaccine,O
platforms,O
can,O
ramp,O
up,O
production,O
rapidly,O
as,O
no,O
cell,O
incubation,O
is,O
required,O
.,O
Developing,O
recombinantsubunit,O
vaccines,O
require,O
cell,O
culture,O
or,O
fermentation,O
process,O
which,O
can,O
take,O
longer,O
.,O
Currently,DATE
multiple,O
development,O
platforms,O
are,O
being,O
utilized,O
[,O
20,NUMBER
],O
.,O
Experts,O
estimate,O
that,O
it,O
can,O
take,O
1218,DATE
months,DURATION
to,O
develop,O
a,O
successful,O
vaccine,O
ready,O
for,O
the,O
general,TITLE
population,O
.,O
There,O
are,O
currently,DATE
as,O
many,O
as,O
70,NUMBER
vaccine,O
candidates,O
in,O
the,O
preclinical,O
stage,O
.,O
Some,O
of,O
the,O
Bacillus,O
Calmete,O
‐,O
Guerin,PERSON
(,O
BCG,O
),O
.,O
a,O
live,O
attenuated,O
vaccine,O
originally,O
used,O
against,O
tuberculosis,CAUSE_OF_DEATH
.,O
is,O
being,O
repurposed,O
against,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
There,O
are,O
several,O
ongoing,O
phase,O
III,NUMBER
clinical,O
trials,O
internationally,O
(,O
NCT04327206,O
.,O
NCT04348370,O
.,O
NCT04328441,O
),O
recruit,O
‐,O
ing,O
healthcare,O
workers,O
as,O
participants,O
.,O
Ad5,O
‐,O
nCoV,O
is,O
an,O
aden,O
‐,O
ovirus,O
type,O
‐,O
5,NUMBER
vector,O
‐,O
based,O
recombinant,O
vaccine,O
engineered,O
to,O
pro,O
‐,O
duce,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
spike,O
protein,O
developed,O
by,O
CanSino,ORGANIZATION
Biologics,ORGANIZATION
in,O
China,COUNTRY
.,O
The,O
vaccine,O
completed,O
recruitment,O
for,O
the,O
phase,O
I,O
trial,O
(,O
single,O
center,O
.,O
open,O
label,O
.,O
dose,O
escalation,O
),O
in,O
China,COUNTRY
.,O
It,O
has,O
commenced,O
to,O
a,O
double,O
‐,O
blind,O
.,O
phase,O
II,NUMBER
RCT,O
(,O
NCT04341389,O
),O
and,O
plan,O
to,O
enroll,O
500,NUMBER
healthy,O
subjects,O
.,O
(,O
NCT04283461,O
),O
is,O
now,DATE
recruiting,O
candidates,O
across,O
the,O
United,COUNTRY
States,COUNTRY
.,O
The,O
vaccine,O
candidate,TITLE
was,O
developed,O
by,O
ModernaTX,O
and,O
supported,O
by,O
NIH,ORGANIZATION
.,O
I,O
/,O
II,NUMBER
single,O
‐,O
blind,O
‐,O
ed,O
.,O
RCT,O
(,O
NCT04324606,O
),O
.,O
The,O
study,O
involves,O
3,NUMBER
arms,O
with,O
5,NUMBER
interven,O
‐,O
tions,O
.,O
The,O
study,O
plans,O
to,O
recruit,O
510,NUMBER
healthy,O
volunteers,O
in,O
Eng,O
‐,O
land,O
.,O
INO,O
‐,O
4800,DATE
.,O
a,O
DNA,O
vaccine,O
candidate,TITLE
developed,O
by,O
Inovio,PERSON
Pharmaceuticals,O
.,O
is,O
being,O
studied,O
in,O
an,O
open,O
‐,O
label,O
phase,O
I,O
trial,O
(,O
NCT04336410,O
),O
to,O
evaluate,O
the,O
safe,O
.,O
tolerability,O
and,O
immunogenic,O
‐,O
ity,O
of,O
the,O
vaccine,O
.,O
The,O
vaccine,O
is,O
administered,O
intradermally,O
followed,O
by,O
electroporation,O
.,O
It,O
plans,O
to,O
recruit,O
40,NUMBER
healthy,O
vol,O
‐,O
unteers,O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
LV,O
vaccine,O
(,O
LV,O
‐,O
SMENP,O
),O
is,O
made,O
by,O
modifying,O
dendritic,O
cells,O
with,O
lentivirus,O
vector,O
expressing,O
COVID,O
‐,O
19,NUMBER
minigene,O
protein,O
from,O
Covid,O
‐,O
19,NUMBER
to,O
activate,O
T,O
cells,O
.,O
The,O
phase,O
I,O
/,O
II,NUMBER
study,O
(,O
NCT04276896,O
),O
plans,O
to,O
recruit,O
100,NUMBER
participants,O
in,O
Shenzhen,CITY
.,O
China,COUNTRY
.,O
COVID,O
‐,O
19,NUMBER
in,O
Cancer,CAUSE_OF_DEATH
Patients,O
Patients,O
with,O
cancer,CAUSE_OF_DEATH
are,O
particularly,O
vulnerable,O
with,O
increased,O
mortality,O
asso,O
‐,O
ciated,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
relative,O
to,O
the,O
general,TITLE
popula,O
‐,O
tion,O
.,O
Cancer,CAUSE_OF_DEATH
patients,O
are,O
typically,O
Chi,PERSON
et,O
al,O
.,O
immunosuppressed,O
with,O
high,O
healthcare,O
utilization,O
requirements,O
which,O
likely,O
con,O
‐,O
tributes,O
to,O
high,O
transmission,O
rates,O
and,O
poorer,O
outcomes,O
.,O
Both,O
Chinese,NATIONALITY
and,O
Italian,NATIONALITY
data,O
demonstrated,O
that,O
the,O
mortality,O
rate,O
of,O
cancer,CAUSE_OF_DEATH
patients,O
with,O
COVID,O
19,NUMBER
were,O
39,PERCENT
%,PERCENT
and,O
20,PERCENT
%,PERCENT
although,O
the,O
sam,O
‐,O
ple,O
size,O
was,O
smaller,O
with,O
different,O
demographics,O
[,O
21.22,NUMBER
],O
.,O
Both,O
the,O
American,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Clinical,ORGANIZATION
Oncology,ORGANIZATION
(,O
ASCO,ORGANIZATION
),O
and,O
the,O
American,NATIONALITY
Society,ORGANIZATION
of,ORGANIZATION
Hematology,ORGANIZATION
(,O
ASH,O
),O
have,O
provided,O
institutional,O
policy,O
recommendations,O
to,O
guide,TITLE
the,O
timing,O
of,O
initiation,O
of,O
treatment,O
and,O
alternatives,O
to,O
standard,O
treatment,O
regimens,O
during,O
this,O
time,O
when,O
resources,O
are,O
limited,O
and,O
risk,O
of,O
potentially,O
life,O
‐,O
threaten,O
‐,O
ing,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
is,O
high,O
.,O
In,O
addition,O
.,O
the,O
FDA,ORGANIZATION
has,O
provided,O
general,TITLE
guidance,O
as,O
to,O
the,O
management,O
of,O
clinical,O
trials,O
during,O
the,O
pandemic,O
.,O
many,O
of,O
which,O
are,O
no,O
longer,O
accruing,O
or,O
temporarily,O
on,O
hold,O
.,O
At,O
the,O
present,DATE
time,O
.,O
cancer,CAUSE_OF_DEATH
patients,O
are,O
eligible,O
for,O
the,O
vast,O
majority,O
of,O
COVID,O
‐,O
19,NUMBER
clinical,O
trials,O
regardless,O
of,O
can,O
‐,O
cer,O
directed,O
treatment,O
status,O
.,O
In,O
the,O
United,COUNTRY
States,COUNTRY
there,O
are,O
currently,DATE
2,NUMBER
intervention,O
studies,O
specifically,O
designed,O
for,O
cancer,CAUSE_OF_DEATH
patients,O
and,O
there,O
are,O
8,NUMBER
observational,O
studies,O
specifically,O
The,O
COVID,O
‐,O
19,NUMBER
pandemic,O
is,O
wreaking,O
havoc,O
across,O
the,O
world,O
.,O
causing,O
high,O
number,O
of,O
morbidities,O
and,O
mortalities,O
.,O
It,O
is,O
the,O
greatest,O
global,O
health,O
crisis,O
of,O
our,O
generation,O
.,O
The,O
case,O
fatality,O
rate,O
is,O
estimated,O
to,O
be,O
3,PERCENT
10,PERCENT
%,PERCENT
.,O
However,O
.,O
given,O
the,O
extremely,O
high,O
infec,O
‐,O
tious,O
rate,O
.,O
there,O
are,O
now,DATE
over,O
2.5,NUMBER
million,NUMBER
confirmed,O
cases,O
with,O
staggering,O
175.000,NUMBER
deaths,O
worldwide,O
as,O
of,O
April,DATE
20,DATE
.,DATE
2020,DATE
.,O
For,O
on,O
‐,O
cology,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
the,O
case,O
fatality,O
rate,O
is,O
even,O
higher,O
.,O
especially,O
those,O
who,O
are,O
on,O
active,O
chemotherapy,O
treat,O
‐,O
ment,O
.,O
The,O
mortality,O
rate,O
of,O
hospitalized,O
COVID,O
‐,O
19,NUMBER
cancer,CAUSE_OF_DEATH
patients,O
can,O
be,O
as,O
high,O
as,O
30,PERCENT
%,PERCENT
(,O
our,O
own,O
institutional,O
data,O
;,O
n,O
=,O
30,NUMBER
),O
.,O
Heath,PERSON
care,O
centers,O
across,O
the,O
globe,O
are,O
using,O
various,O
agents,O
to,O
treat,O
COVID,O
‐,O
19,NUMBER
as,O
there,O
are,O
no,O
effective,O
therapies,O
to,O
date,O
with,O
strong,O
evidence,O
.,O
However,O
.,O
it,O
is,O
encouraging,O
to,O
see,O
the,O
high,O
volume,O
and,O
speed,O
of,O
the,O
ongoing,O
clinical,O
trials,O
.,O
High,O
quality,O
evidence,O
‐,O
based,O
guidelines,O
are,O
needed,O
urgently,O
to,O
standardize,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
especially,O
for,O
this,O
vulnerable,O
oncology,O
patient,O
popula,O
‐,O
tion,O
.,O
This,O
study,O
is,O
supported,O
by,O
US,ORGANIZATION
NIH,ORGANIZATION
grants,O
2UG1CA189850,O
.,O
1,NUMBER
.,O
COVID,O
‐,O
19,NUMBER
Map,O
[,O
Internet,MISC
],O
.,O
Johns,ORGANIZATION
Hopkins,ORGANIZATION
Coronavirus,ORGANIZATION
Resource,ORGANIZATION
Cen,ORGANIZATION
‐,O
ter,TITLE
.,O
[,O
cited,O
2020,DATE
Apr,DATE
22,DATE
],O
.,O
2,NUMBER
.,O
Garg,PERSON
S,O
Hospitalization,O
Rates,O
and,O
Characteristics,O
of,O
Patients,O
Hospitalized,O
with,O
LaboratoryConfirmed,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
COVID,O
‐,O
NET,O
.,O
14,NUMBER
States,O
.,O
March,DATE
130,DATE
.,DATE
2020,DATE
.,O
MMWR,ORGANIZATION
3,NUMBER
.,O
Imbalanced,O
host,TITLE
response,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
drives,O
development,O
of,O
COVID,O
‐,O
19,NUMBER
Immunology,O
Chi,O
et,O
al,O
.,O
5,NUMBER
.,O
Vincent,PERSON
MJ,PERSON
.,O
Bergeron,PERSON
E,O
.,O
Benjannet,O
S,O
.,O
Erickson,PERSON
BR,PERSON
.,O
Rollin,ORGANIZATION
PE,ORGANIZATION
.,O
Ksiazek,PERSON
TG,PERSON
.,O
et,O
al,O
.,O
Chloro,O
‐,O
quine,O
is,O
a,O
6,NUMBER
.,O
Wang,PERSON
M,O
.,O
Cao,PERSON
R,PERSON
.,O
Zhang,PERSON
L,PERSON
.,O
Yang,PERSON
X,PERSON
.,O
Liu,PERSON
J,PERSON
.,O
Xu,O
M,O
.,O
et,O
al,O
.,O
Remdesivir,O
and,O
chloroquine,O
effectively,O
inhibit,O
the,O
recently,DATE
emerged,O
novel,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
in,O
vitro,O
.,O
Cell,O
Reserach,O
.,O
2020,DATE
7,NUMBER
.,O
Yao,PERSON
X,PERSON
.,O
Ye,PERSON
F,PERSON
.,O
Zhang,O
M,O
.,O
Cui,PERSON
C,PERSON
.,O
Huang,PERSON
B,PERSON
.,O
Niu,PERSON
P,O
.,O
et,O
al,O
.,O
In,O
vitro,O
antiviral,O
activity,O
and,O
projection,O
of,O
optimized,O
dosing,O
de,O
‐,O
sign,O
of,O
hydroxychloroquine,O
for,O
the,O
treatment,O
of,O
severe,O
acute,O
res,O
‐,O
piratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
Clinical,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
2020,DATE
3,NUMBER
9,NUMBER
.,O
8,NUMBER
.,O
Gautret,O
P,O
.,O
Lagier,PERSON
J,O
‐,O
C,O
.,O
Parola,PERSON
P,O
.,O
Hoang,PERSON
VT,STATE_OR_PROVINCE
.,O
Meddeb,PERSON
L,PERSON
.,O
Mailhe,O
M,O
.,O
et,O
al,O
.,O
Hydroxychloroquine,PERSON
and,O
azithromycin,O
as,O
a,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
results,O
of,O
an,O
open,O
‐,O
label,O
non,O
‐,O
randomized,O
clinical,O
trial,O
.,O
9,NUMBER
.,O
Early,O
treatment,O
of,O
1061,DATE
COVID,O
‐,O
19,NUMBER
patients,O
with,O
hydroxychloroquine,O
and,O
azithromycin,O
.,O
Mar,DATE
‐,O
seille,O
.,O
11,NUMBER
.,O
Mulangu,O
S,O
.,O
Dodd,ORGANIZATION
LE,ORGANIZATION
.,O
Davey,ORGANIZATION
RT,ORGANIZATION
.,O
Tshiani,PERSON
Mbaya,PERSON
O,O
.,O
Proschan,O
M,O
.,O
Mukadi,PERSON
D,PERSON
.,O
et,O
al,O
.,O
A,O
randomized,O
.,O
12,NUMBER
.,O
Holshue,ORGANIZATION
ML,ORGANIZATION
.,O
DeBolt,PERSON
C,O
.,O
Lindquist,PERSON
S,O
.,O
Lofy,LOCATION
KH,LOCATION
.,O
Wiesman,PERSON
J,PERSON
.,O
Bruce,PERSON
H,PERSON
.,O
et,O
al,O
.,O
First,ORDINAL
case,O
of,O
2019,DATE
novel,O
13,NUMBER
.,O
Kujawski,ORGANIZATION
SA,ORGANIZATION
.,O
Wong,ORGANIZATION
KK,ORGANIZATION
.,O
Collins,ORGANIZATION
JP,ORGANIZATION
.,O
Epstein,PERSON
L,PERSON
.,O
Killerby,O
ME,STATE_OR_PROVINCE
.,O
Midgley,PERSON
CM,O
.,O
et,O
al,O
.,O
First,ORDINAL
12,NUMBER
patients,O
with,O
coron,O
‐,O
avirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
medRxiv,O
.,O
2020,DATE
3,NUMBER
SARS,O
coronavirus,O
and,O
MERS,O
coronavirusA,O
possible,O
reference,O
for,O
coronavirus,O
disease,CAUSE_OF_DEATH
‐,O
19,DATE
15,DATE
.,O
Cao,PERSON
B,PERSON
.,O
Wang,O
Y,O
.,O
Wen,PERSON
D,PERSON
.,O
Liu,PERSON
W,PERSON
.,O
Wang,PERSON
J,O
.,O
Fan,O
G,O
.,O
et,O
al,O
.,O
A,O
trial,O
of,O
lopinavirritonavir,O
in,O
adults,O
16,NUMBER
.,O
Xu,PERSON
X,O
.,O
Han,O
M,O
.,O
Li,PERSON
T,PERSON
.,O
Sun,PERSON
W,PERSON
.,O
Wang,PERSON
D,O
.,O
Fu,O
B,O
.,O
et,O
al,O
.,O
Effective,O
treatment,O
of,O
severe,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
tocilizumab,O
.,O
Proceedings,O
of,O
the,O
National,ORGANIZATION
Academy,ORGANIZATION
of,ORGANIZATION
Sciences,ORGANIZATION
.,O
2020,DATE
4,NUMBER
29,NUMBER
.,O
17,NUMBER
.,O
Zhou,O
Y,O
.,O
Hou,O
Y,O
.,O
Shen,PERSON
J,O
.,O
Huang,PERSON
Y,PERSON
.,O
Martin,PERSON
W,PERSON
.,O
Cheng,ORGANIZATION
F.,ORGANIZATION
Network,ORGANIZATION
‐,O
based,O
drug,O
repurposing,O
for,O
novel,O
coronavirus,O
2019,DATE
‐,O
nCoV,O
/,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Cell,O
Discovery,O
.,O
2020,DATE
3,NUMBER
16,NUMBER
;,O
6,NUMBER
(,O
1,NUMBER
),O
:,O
118,NUMBER
.,O
[,O
PubMed,O
:,O
31934347,NUMBER
],O
18,NUMBER
.,O
Mair,PERSON
‐,O
Jenkins,PERSON
J,PERSON
.,O
Saavedra,PERSON
‐,O
Cam,O
‐,O
pos,O
M,O
.,O
Baillie,PERSON
JK,PERSON
.,O
Cleary,PERSON
P,O
.,O
Khaw,PERSON
F,O
‐,O
M,O
.,O
Lim,PERSON
WS,PERSON
.,O
et,O
al,O
.,O
The,O
Effec,O
‐,O
tiveness,O
of,O
Convalescent,O
Plasma,O
and,O
Hyperimmune,PERSON
Immunoglobulin,PERSON
for,O
the,O
Treatment,O
of,O
19,NUMBER
.,O
Shen,O
C,O
.,O
Wang,PERSON
Z,PERSON
.,O
Zhao,PERSON
F,O
.,O
Yang,O
Y,O
.,O
Li,PERSON
J,PERSON
.,O
Yuan,O
J,O
.,O
Wang,PERSON
F,O
.,O
Li,PERSON
D,O
.,O
Yang,PERSON
M,O
.,O
Xing,PERSON
L,PERSON
.,O
Wei,O
J.,O
Treatment,O
of,O
5,NUMBER
crit,O
‐,O
ically,O
ill,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
with,O
convalescent,O
plasma,O
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
4,NUMBER
20,NUMBER
.,O
Lurie,PERSON
N,O
.,O
Saville,PERSON
M,O
.,O
Hatchett,PERSON
R,PERSON
.,O
Halton,PERSON
J.,PERSON
Developing,PERSON
Covid,O
‐,O
19,NUMBER
Vaccines,O
at,O
Pandemic,O
Speed,O
.,O
New,O
21,NUMBER
.,O
Liang,PERSON
W,PERSON
.,O
Guan,PERSON
W,PERSON
.,O
Chen,PERSON
R,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
Li,PERSON
J,PERSON
.,O
Xu,PERSON
K,PERSON
.,O
et,O
al,O
.,O
Cancer,CAUSE_OF_DEATH
patients,O
in,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
nationwide,O
analysis,O
in,O
China,COUNTRY
.,O
Lancet,O
Oncology,O
.,O
2020,DATE
3,NUMBER
1,NUMBER
;,O
21,NUMBER
(,O
3,NUMBER
),O
:,O
3357,DATE
.,O
[,O
PubMed,O
:,O
32066541,NUMBER
],O
22,NUMBER
.,O
Italian,NATIONALITY
Oncologists,MISC
Cau,MISC
‐,O
tionary,O
Advice,O
on,O
COVID,O
‐,O
19,NUMBER
for,O
US,COUNTRY
Centers,O
[,O
Internet,MISC
],O
.,O
Medscape,ORGANIZATION
[,O
cited,O
Abbott,ORGANIZATION
Laboratories,ORGANIZATION
Pharm,ORGANIZATION
standard,O
Ono,O
Pharmaceutical,O
Camostat,O
Mesylate,O
Recombinant,O
/,O
modified,O
‐,O
IL,STATE_OR_PROVINCE
‐,O
1,NUMBER
inhibitor,O
Swedish,NATIONALITY
Orphan,O
Monoclonal,O
antibody,O
‐,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
inhibitor,O
Monoclonal,O
antibody,O
‐,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
inhibitor,O
Serine,MISC
protease,O
inhibitor,O
Antiviral,O
‐,O
HIV,CAUSE_OF_DEATH
protease,O
inhibitor,O
Antiviral,O
‐,O
Adenosine,LOCATION
nucleotide,O
Analogue,O
Block,O
RNA,O
de,O
‐,O
pendent,O
RNA,O
Antiviral,O
Inhibit,O
viral,O
entry,O
and,O
endocytosis,O
as,O
well,O
as,O
host,TITLE
immunomodulatory,O
effects,O
Class,O
of,O
Agent,O
Drugs,CRIMINAL_CHARGE
against,O
cy,O
‐,O
tokine,O
storm,CAUSE_OF_DEATH
Gilead,ORGANIZATION
Science,ORGANIZATION
Available,ORGANIZATION
as,O
generic,O
drug,O
Drugs,CRIMINAL_CHARGE
against,O
COVID19,O
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
10,NUMBER
Phase,O
III,NUMBER
=,O
11,NUMBER
Phase,O
IV,O
=,O
6,NUMBER
Not,O
applicable,O
=,O
5,NUMBER
Phase,O
I,O
=,O
0,NUMBER
Phase,O
II,NUMBER
=,O
0,NUMBER
Phase,O
III,NUMBER
=,O
0,NUMBER
Phase,O
IV,O
=,O
3,NUMBER
Not,O
ap,O
‐,O
plicable,O
=,O
1,NUMBER
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
1,NUMBER
Phase,O
III,NUMBER
=,O
1,NUMBER
Phase,O
IV,O
=,O
1 9/30,NUMBER
not,O
yet,O
recruiting,O
1/30,NUMBER
.,O
not,O
recruiting,O
2/30,NUMBER
enrolling,O
by,O
invitation,O
1/4,NUMBER
enrolling,O
by,O
invitation,O
not,O
yet,O
recruiting,O
2/4,NUMBER
not,O
yet,O
recruiting,O
Approved,O
to,O
treat,O
in,O
‐,O
fluenza,O
in,O
China,COUNTRY
and,O
Russia,COUNTRY
Chronic,O
pancreatitis,CAUSE_OF_DEATH
.,O
postop,O
reflux,O
Phase,O
I,O
=,O
0,NUMBER
Phase,O
II,NUMBER
=,O
6,NUMBER
Phase,O
III,NUMBER
=,O
5,NUMBER
(,O
phase,O
II,NUMBER
/,O
III,NUMBER
trials,O
),O
Phase,O
IV,O
=,O
1,NUMBER
1/6,O
not,O
yet,O
recruiting,O
2/8,NUMBER
not,O
yet,O
recruiting,O
1/8,NUMBER
not,O
recruiting,O
Active,O
Rheumatoid,O
Arthritis,O
.,O
Cryopyrin,O
‐,O
Associated,O
Periodic,O
Active,O
Rheumatoid,O
Arthritis,O
Phase,O
I,O
=,O
0,NUMBER
Phase,O
II,NUMBER
=,O
3,NUMBER
Phase,O
III,NUMBER
=,O
3,NUMBER
3/22,NUMBER
not,O
yet,O
recruiting,O
1/22,NUMBER
not,O
recruiting,O
3/33,NUMBER
enrolling,O
by,O
invitation,O
Cytokine,O
Release,O
Syndrome,O
.,O
Giant,O
Cell,O
Arteritis,O
.,O
Polyarticular,PERSON
juvenile,O
idiopathic,O
arthritis,O
.,O
Rheumatoid,O
arthritis,O
.,O
Systemic,O
ju,O
‐,O
venile,O
idiopathic,O
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
13,NUMBER
Phase,O
III,NUMBER
=,O
5,NUMBER
Phase,O
IV,O
=,O
1,NUMBER
Not,O
applicable,O
=,O
1,NUMBER
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
2,NUMBER
Phase,O
III,NUMBER
=,O
8,NUMBER
Conditionally,O
approved,O
for,O
Ebola,MISC
in,O
the,O
US,COUNTRY
1/10,NUMBER
enrolling,O
by,O
invitation,O
Current,DATE
Phases,O
Phase,O
II,NUMBER
=,O
18,NUMBER
Phase,O
III,NUMBER
=,O
22,NUMBER
Phase,O
IV,O
=,O
7,NUMBER
Not,O
applicable,O
=,O
2,NUMBER
Num,O
‐,O
ber,O
of,O
active,O
trials,O
(,O
N,O
),O
22/45,NUMBER
not,O
yet,O
recruiting,O
3/45,NUMBER
enrolling,O
by,O
invitation,O
Lupus,CAUSE_OF_DEATH
erythematosus,CAUSE_OF_DEATH
.,O
Rheumatoid,O
Arthritis,O
.,O
Malaria,CAUSE_OF_DEATH
Approved,O
use,O
Summary,O
of,O
agents,O
that,O
are,O
under,O
investigation,O
and,O
number,O
of,O
available,O
studies,O
.,O
Total,O
numbers,O
of,O
trials,O
and,O
recruit,O
‐,O
ing,O
and,O
phases,O
may,O
vary,O
depending,O
on,O
Chi,PERSON
et,O
al,O
.,O
Convalescent,O
Plasma,O
Trials,O
Various,O
institutions,O
and,O
Blood,O
Centers,O
around,O
the,O
Bruton,ORGANIZATION
Tyrosine,ORGANIZATION
Kinase,ORGANIZATION
Inhibitor,ORGANIZATION
Tyrosine,ORGANIZATION
Kinase,ORGANIZATION
Inhibitor,ORGANIZATION
‐,O
JAK1,O
.,O
JAK,O
2,NUMBER
Selective,O
Nuclear,O
Export,O
(,O
SINE,O
),O
Karyopharm,O
Therapeutics,O
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
4,NUMBER
Phase,O
III,NUMBER
=,O
1,NUMBER
Not,O
applicable,O
=,O
1 4/8,NUMBER
not,O
yet,O
re,O
‐,O
cruiting,O
N,O
=,O
1,NUMBER
.,O
not,O
yet,O
recruiting,O
Myelofibrosis,MISC
.,O
Polycythemia,PERSON
Ve,PERSON
‐,PERSON
ra,O
.,O
Acute,O
graft,O
versus,O
host,TITLE
disease,CAUSE_OF_DEATH
Mantle,O
Cell,O
Lymphoma,CAUSE_OF_DEATH
.,O
Chronic,O
Leukemia,CAUSE_OF_DEATH
.,O
Small,O
Lymphocytic,O
10/84,NUMBER
not,O
yet,O
recruiting,O
4/84,NUMBER
not,O
re,O
‐,O
cruiting,O
Phase,O
II,NUMBER
=,O
2 1/2,NUMBER
not,O
yet,O
recruiting,O
Multiple,CAUSE_OF_DEATH
myeloma,CAUSE_OF_DEATH
.,O
in,O
‐,O
vestigation,O
for,O
Phase,O
I,O
=,O
12,NUMBER
Phase,O
II,NUMBER
=,O
35,NUMBER
Phase,O
III,NUMBER
=,O
12,NUMBER
Phase,O
IV,O
=,O
1,NUMBER
Not,O
applicable,O
=,O
15,NUMBER
Phase,O
I,O
=,O
0,NUMBER
Phase,O
II,NUMBER
=,O
1,NUMBER
Phase,O
III,NUMBER
=,O
0,NUMBER
Current,O
Phases,O
Number,O
of,O
active,O
trials,O
(,O
N,O
),O
Approved,O
use,O
Class,O
of,O
Agent,O
Chi,O
et,O
al,O
.,O
Inovio,ORGANIZATION
Pharmaceuticals,ORGANIZATION
LV,ORGANIZATION
vaccine,O
(,O
LV,O
‐,O
SMENP,O
),O
Lentiviral,O
vec,O
‐,O
tor,O
‐,O
based,O
vaccine,O
DNA,O
vaccine,O
N,O
=,O
2,NUMBER
.,O
recruiting,O
N,O
=,O
1,NUMBER
.,O
recruiting,O
Phase,O
I,O
=,O
2,NUMBER
Phase,O
II,NUMBER
=,O
1,NUMBER
Phase,O
I,O
/,O
II,NUMBER
=,O
1 1/2,NUMBER
not,O
yet,O
recruiting,O
ChA,O
‐,O
dOx1,O
nCoV,O
‐,O
19,NUMBER
Adenovirus,O
vector,O
‐,O
based,O
vaccine,O
mRNA,O
based,O
vaccine,O
Kaiser,ORGANIZATION
Permanente,ORGANIZATION
/,ORGANIZATION
Washington,ORGANIZATION
Health,ORGANIZATION
Research,ORGANIZATION
Phase,ORGANIZATION
I,O
Phase,O
I,O
=,O
1,NUMBER
Phase,O
II,NUMBER
=,O
1 1/2,NUMBER
not,O
yet,O
recruiting,O
Adenovirus,O
vector,O
‐,O
based,O
recom,O
‐,O
binant,O
CanSino,O
Biologics,O
N,O
=,O
1,NUMBER
.,O
recruiting,O
Phase,O
II,NUMBER
/,O
III,NUMBER
N,O
=,O
3,NUMBER
.,O
2,NUMBER
are,O
recruiting,O
Live,O
‐,O
Attenuated,O
.,O
repurposed,O
vaccine,O
Massachusetts,STATE_OR_PROVINCE
Gen,TITLE
‐,O
eral,O
Hospital,O
Phases,O
of,O
Trials,O
Bacillus,O
Calmette,O
‐,O
Guerin,PERSON
(,O
BCG,O
),O
NCT04327206,O
.,O
NCT04348370,O
.,O
NCT04328441,O
Trials,O
(,O
N,O
),O
and,O
status,O
Vac,O
‐,O
cine,O
Trials,O
Summary,O
of,O
trials,O
that,O
are,O
currently,DATE
in,O
the,O
clinical,O
phases,O
of,O
vaccine,O
development,O
.,O
Chi,O
et,O
al,O
.,O
Anti,O
‐,O
Interleukin,O
‐,O
8,NUMBER
(,O
Anti,O
‐,O
IL,STATE_OR_PROVINCE
‐,O
8,NUMBER
),O
for,O
Cancer,CAUSE_OF_DEATH
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
Phase,O
III,NUMBER
DAS181,O
Lower,O
Tract,O
PIV,O
Infection,CAUSE_OF_DEATH
in,O
Immunocompromised,O
Subjects,O
COVID,O
‐,O
19,NUMBER
Sub,O
study,O
Study,O
Title,O
Not,O
yet,O
Percent,O
of,O
subjects,O
who,O
Return,O
to,O
Room,O
Air,O
Percent,O
of,O
subjects,O
with,O
improved,O
COVID,O
‐,O
19,NUMBER
Clinical,O
Sta,O
‐,O
tus,O
Scale,O
(,O
sub,O
‐,O
study,O
),O
Time,O
to,O
Improvement,O
in,O
the,O
7,NUMBER
‐,O
point,O
ordinal,O
scale,O
Time,O
to,O
Death,MISC
Time,MISC
to,O
Intubation,O
Proportion,O
of,O
patients,O
re,O
‐,O
quiring,O
ICU,O
admission,O
Mortality,O
at,O
1,NUMBER
Documented,O
solid,O
tumor,CAUSE_OF_DEATH
(,O
lo,O
‐,O
calized,O
or,O
metastatic,O
),O
or,O
hematologic,O
malignancy,O
within,O
the,O
last,O
3,DURATION
years,DURATION
.,O
Prior,O
definitive,O
treatment,O
for,O
localized,O
disease,CAUSE_OF_DEATH
is,O
al,O
‐,O
lowed,O
(,O
with,O
the,O
exception,O
of,O
non,O
‐,O
melanoma,CAUSE_OF_DEATH
skin,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
.,O
low,O
risk,O
prostate,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
or,O
non,O
‐,O
muscle,O
invasive,O
bladder,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
),O
and,O
must,O
have,O
occurred,O
within,O
3,DURATION
years,DURATION
of,O
enrollment,O
.,O
Immunocompromised,O
(,O
history,O
of,O
hematopoietic,O
stem,O
cell,O
transplantation,O
.,O
solid,O
organ,O
transplant,O
.,O
history,O
of,O
treatment,O
for,O
solid,O
or,O
hematologic,O
malig,O
‐,O
nancy,O
or,O
immunodeficiency,O
due,O
to,O
congenital,O
Oncologic,O
Eligibility,O
Criteria,O
Current,DATE
list,O
of,O
interventional,O
COVID,O
‐,O
19,NUMBER
studies,O
specifi,O
‐,O
cally,O
enrolling,O
cancer,CAUSE_OF_DEATH
patients,O
in,O
the,O
United,COUNTRY
States,COUNTRY
Chi,LOCATION
et,O
al,O
.,O
